Gero, a biotech company applying AI and large-scale human data to develop therapies that extend healthy human lifespan, has appointed a Principal Target ID Scientist to strengthen its target discovery capabilities.
The role enhances Gero’s ability to translate multi-omics and human genetic data into validated, causally linked drug targets. By integrating advanced computational approaches with experimental insight, the appointment improves target prioritization, streamlines program decision-making, and reduces early-stage attrition risk.
This strengthens Gero’s capacity to expand its discovery pipeline with greater precision and speed, supporting the development of first-in-class therapeutics.
As a result of their support, we have successfully filled several key roles with high-quality hires who continue to make meaningful contributions to our organization
